Antimetabolite combination chemotherapy

This page covers all Antimetabolite combination chemotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Thymidylate synthase, dihydrofolate reductase.

Targets

Thymidylate synthase, dihydrofolate reductase

Phase 3 pipeline (1)

• MTX + 5-FU sequential therapy · Japan Clinical Oncology Group · Oncology
  MTX + 5-FU sequential therapy combines methotrexate and 5-fluorouracil administered in sequence to inhibit nucleotide synthesis and DNA replication in cancer cells.

Patent intelligence

• antimetabolite combination chemotherapy patent landscape — aggregated cliff calendar, attackable patents, originator estates